Nov 10, 2025 07:02AM MeiraGTx partners with Eli Lilly on eye disease gene therapies

Oct 20, 2025 04:08PM Raymond James Starts MeiraGTx Holdings plc (MGTX) at Strong Buy, PT $29

Jun 9, 2025 06:05AM Lucid Capital Markets Starts MeiraGTx Holdings plc (MGTX) at Buy

May 13, 2025 05:24PM MeiraGTx Holdings plc (MGTX) Misses Q1 EPS by 62c

May 9, 2025 08:01AM MeiraGTx Holdings plc (MGTX) Granted FDA RMAT Designation for AAV-GAD for the Treatment of Parkinson’s Disease

Mar 17, 2025 09:15AM MeiraGTx Holdings plc (MGTX) PT Raised to $13 at RBC Capital; 'PD Deal Looks Good To Us'

Mar 13, 2025 07:31AM MeiraGTx Holdings plc (MGTX) Enters into a Strategic Collaboration with Hologen AI

Mar 12, 2025 09:23AM Piper Sandler on MeiraGTx Holdings (MGTX): 'We See Meaningful Upside to the Stock (Ahead of Pivotal Data)'

Jan 22, 2025 08:30AM MeiraGTx Holdings (MGTX) Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Dec 9, 2024 08:07AM MeiraGTx Holdings plc (MGTX) Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Oct 15, 2024 07:01AM MeiraGTx Holdings plc (MGTX) Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease

Oct 11, 2024 07:45AM Piper Sandler Reiterates Overweight Rating on MeiraGTx Holdings plc (MGTX)

Aug 13, 2024 06:26AM MeiraGTx Holdings plc (MGTX) PT Lowered to $9 at RBC Capital

Aug 12, 2024 07:10AM MeiraGTx Holdings plc (MGTX) Announces 12.5M Share Offering at $4/sh

Aug 12, 2024 07:08AM MeiraGTx Holdings plc (MGTX) Misses Q2 EPS by 36c

Jul 31, 2024 05:44AM Chardan Capital Markets Assumes MeiraGTx Holdings plc (MGTX) at Buy